Oricula Therapeutics
Oricula Therapeutics is a start-up biotechnology company with a mission to develop medicines that protect hearing and balance from the effects of ototoxic drugs and aging. They have developed the first medication to prevent hearing loss in patients undergoing treatment for serious infections with aminoglycoside antibiotics.
Team Members
Malcolm Gleser,
CEO
Edwin Rubel
Co-founder, Virginia Merrill Bloedel Professor of Hearing Sciences, University of Washington
David Raible
Co-founder, Professor of Biological Structure, University of Washington
Henry Ou
Associate Professor of Pediatric Otolaryngology at University of Washington and Seattle Children’s Hospital
Julian Simon
Fred Hutchinson Cancer Research Center
Vince Groppi
University of Michigan
Graham Johnson
Marc Bailie
Michigan State University
Judd Walson
Associate Professor of Global Health, Medicine, Pediatrics, and Epidemiology, University of Washington